Issue Archive
August 2023 | Volume 22 | Issue 8
Editorials
Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study
The early phase of the COVID-19 pandemic prompted a repurposing of antiviral and immunomodulatory drugs as investigational therapeutics, including hydroxychloroquine and chloroquine. While antimalaria...
Read MoreThe Patient-Physician Relationship and Adherence: Observations From a Clinical Study
Improved patient-physician relationships (PPR) are associated with better patient satisfaction and disease outcomes, however, there is limited literature assessing how PPR affects adherence in dermato...
Read MoreNo Racial Differences Found in Access to Biologics: A Population-Based Study of Psoriasis Patients in the United States
Background: Conflicting evidence exists regarding the role of race in access to biologics for patients with psoriasis. Objective: To compare biologic use among adult and pediatric United States psoria...
Read More
Original Articles
Dermatology in Contemporary Times: Building Awareness of Social Media's Association With Adolescent Skin Disease and Mental Health
Background: The contribution of psychological disorders to the burden of skin disease has been poorly explored in adolescent patients. The review aims to provide insights into the psychological, socia...
Read MoreTildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis
Background: This prospective, open-label study evaluated the effectiveness and safety of tildrakizumab plus topical halcinonide ointment in psoriasis patients. Methods: Adults (age greater than or eq...
Read MorePsoriasis and Skin Barrier Dysfunction: The Role of Gentle Cleansers and Moisturizers in Treating Psoriasis
Background: Psoriasis is a chronic immune-mediated dermatologic disorder with multisystemic comorbidities, which is effectively treated with a range of prescription therapies. Studies have reported ep...
Read MoreLong-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged ≥ 12 years based on results from two 12-week Phase 3 studies in patients with moderate-to-severe ac...
Read MoreOff-Label Use of Baricitinib in Dermatology
The current US Food and Drug Administration (FDA) indications for baricitinib include alopecia areata, rheumatoid arthritis, and COVID-19. However, increasing evidence indicates that baricitinib is ef...
Read MoreReal-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study
Background: Tildrakizumab is an anti–interleukin-23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. This analysis evaluated real-world effe...
Read MoreA Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults
Psoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque psori...
Read MoreConsensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis
This article aims to provide consensus statements on the use of corticosteroid-containing topical medications for the management of psoriasis. This Psoriasis Expert Group (PEG) includes dermatologist ...
Read MoreDiagnosis and Management of Pediatric Psoriasis: An Overview for Pediatricians
Pediatric psoriasis (PsO) and its associated comorbidities carry physical and psychosocial burdens in children and adolescents, which can negatively impact quality of life. However, features distingui...
Read MoreReview of Superficial Cryotherapy for the Treatment of Alopecia Areata
Cryotherapy has recently been examined as a potential treatment for alopecia areata (AA). AA is classically managed with intralesional or systemic steroids but relapse rates among those with longstand...
Read MoreTapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis
Topical treatments remain the foundation of psoriasis management. Tapinarof (VTAMA®; Dermavant Sciences, Inc.) is a first-in-class, non-steroidal, topical, aryl hydrocarbon receptor (AhR) agonist ...
Read MoreHormonal Treatments in Hidradenitis Suppurativa: A Systematic Review
Background: Hidradenitis suppurativa (HS) is an inflammatory skin condition characterized by recurrent abscesses, nodules, and sinus tracts. Hormones are thought to play an important role in HS pathop...
Read More
Features
Rethinking the Inflammatory Balance in Psoriasis and Atherosclerosis
Guénin S, Kazemi A, Cline A, et al. Rethinking the inflammatory balance in psoriasis and atherosclerosis. J Drugs Dermatol. 2023;22(8):832-833. doi:10.36849/JDD.7082...
Read MoreEXTRA, EXTRA, Treatment Approaches for EXTRAmammary Paget Disease
Desai S, McCormick E, Nelson K, et al. EXTRA, EXTRA, treatment approaches for EXTRAmammary Paget disease. J Drugs Dermatol. 2023;22(8):844-845. doi:10.36849/JDD.2023.NVRN0823...
Read More
Case Reports
Verrucous Psoriasis: Rare Variant and Novel Treatment
Xenopoulou D, Pochat C, Greco E. Verrucous psoriasis: rare variant and novel treatment. J Drugs Dermatol. 2023;22(8):826-827. doi:10.36849/JDD.C6874R1...
Read MoreTalquetamab-Induced Grover's Disease
Kresch M, Guénin S, Mubasher A, et al. Talquetamab-induced Grover’s disease. J Drugs Dermatol. 2023;22(8):828-829. doi:10.36849/JDD.7170...
Read MoreJuvenile Pemphigus Foliaceus in a Patient With Psoriasis Receiving Narrow-Band Ultraviolet-B: Successful Treatment With Rituximab
Pemphigus foliaceus is an autoimmune blistering disease of the skin that is not frequently associated with mucous membrane involvement. It is characterized by immunoglobulin G (IgG) antibodies against...
Read More
Departments
FULL SUPPLEMENT: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment
Most patients with plaque psoriasis exhibit mild-to-moderate disease and topical therapies remain the mainstay treatment option for these patients. The use of topical steroids in combination with vita...
Read MoreFULL SUPPLEMENT: Management of Atopic Dermatitis in People with Skin of Color: A Practical Algorithm
Background: Variations in the epidemiology, clinical presentation, and disease course in skin of color (SOC) atopic dermatitis (AD) patients have been reported that may impact treatment approach and s...
Read More
Supplements
INDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment
Most patients with plaque psoriasis exhibit mild-to-moderate disease and topical therapies remain the mainstay treatment option for these patients. The use of topical steroids in combination with vita...
Read MoreINDIVIDUAL ARTICLE: An Algorithm for the Management of Atopic Dermatitis in People With Skin of Color
Background: Variations in the epidemiology, clinical presentation, and disease course in skin of color (SOC) atopic dermatitis (AD) patients have been reported that may impact treatment approach and s...
Read More
